Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
Key takeaways
- Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc.
- On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc.
- According to Merle, SAB-142 has a substantial opportunity as a potential disease-altering treatment in the type 1 diabetes marketplace.
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) Muhammad Ali Khalid Tue, June 30, 2026 at 11:34 PM GMT+7 2 min read SABS SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside.
On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NASDAQ:SABS) with a target price of $13, and assigned an Overweight rating to the stock. As per Merle's projections, the stock currently offers a highly lucrative upside potential of more than 235%.
According to Merle, SAB-142 has a substantial opportunity as a potential disease-altering treatment in the type 1 diabetes marketplace. The analyst believes that the Phase 2b data, which is anticipated in the latter half of 2027, will be the primary driver for the stock.